2022
Transfusion support for the oncology patient
Stendahl K, Schulz W, Snyder E. Transfusion support for the oncology patient. 2022, 482-488. DOI: 10.1002/9781119719809.ch41.ChaptersOncology patientsTransfusion supportBlood productsRed blood cell transfusionAntibiotic-refractory infectionsAppropriate blood productsChronic transfusion supportMost oncology patientsSignificant transfusion reactionsBlood cell transfusionGranulocyte infusionsCell transfusionSevere neutropeniaOxygen-carrying capacityAppropriate therapyTransfusion therapyTransfusion reactionsPatientsABO antigensABO groupHost antibodiesTransfusion servicesRBC unitsBlood componentsWhole bloodInnate and Adaptive Immunity to Transfused Allogeneic RBCs in Mice Requires MyD88.
Soldatenko A, Hoyt LR, Xu L, Calabro S, Lewis SM, Gallman AE, Hudson KE, Stowell SR, Luckey CJ, Zimring JC, Liu D, Santhanakrishnan M, Hendrickson JE, Eisenbarth SC. Innate and Adaptive Immunity to Transfused Allogeneic RBCs in Mice Requires MyD88. The Journal Of Immunology 2022, 208: 991-997. PMID: 35039331, PMCID: PMC10107373, DOI: 10.4049/jimmunol.2100784.Peer-Reviewed Original ResearchConceptsPattern recognition receptorsDendritic cellsDC activationAdaptive immunityClass of PRRsNon-ABO alloantibodiesRecipient dendritic cellsSplenic dendritic cellsMouse RBCsInflammatory cytokine responseTreatment of anemiaRBC transfusion therapyTransfused RBCsAlloantibody responsesAllogeneic RBCsSerious complicationsCytokine responsesTransfusion therapyRecognition receptorsMyD88TransfusionAlloimmunizationRBCsTRIFUnknown mechanism
2021
Transfusion management for children supported by extracorporeal membrane oxygenation
Karam O, Nellis ME. Transfusion management for children supported by extracorporeal membrane oxygenation. Transfusion 2021, 61: 660-664. PMID: 33491189, DOI: 10.1111/trf.16272.Peer-Reviewed Original Research
2020
The Challenge of Recruiting Convalescent Plasma Donors during the COVID-19 Pandemic: Preliminary Results from a Single Center in Midwest Brazil
do Rosario Ferraz Roberti M, Prudente T, Castro R, Candido M, Rodrigues R, Morelli M, Gonçalves A, de Sá J, de Souza L, Rabahi M, de Moraes Arantes A. The Challenge of Recruiting Convalescent Plasma Donors during the COVID-19 Pandemic: Preliminary Results from a Single Center in Midwest Brazil. Blood 2020, 136: 18-19. PMCID: PMC8330304, DOI: 10.1182/blood-2020-143058.Peer-Reviewed Original ResearchConvalescent plasmaCOVID-19 pandemicSerological screeningConvalescent COVID-19 patientsPositive RT-PCRBlood donationCOVID-19 patientsDonation ratesAwareness-raisingDonation processTransfusion therapySingle centerConvalescent plasma donorsNulliparous donorsPC transfusionRecruiting donorsConvalescent donorsDonor selectionPublic health challengeSelf-interestRecovered patientsExclusion criteriaLists of patientsCOVID-19Plasma donorsImmunohematologic aspects of alloimmunization and alloantibody detection: A focus on pregnancy and hemolytic disease of the fetus and newborn
Gupta GK, Balbuena-Merle R, Hendrickson JE, Tormey CA. Immunohematologic aspects of alloimmunization and alloantibody detection: A focus on pregnancy and hemolytic disease of the fetus and newborn. Transfusion And Apheresis Science 2020, 59: 102946. PMID: 32962917, DOI: 10.1016/j.transci.2020.102946.Peer-Reviewed Original ResearchConceptsRed blood cellsHemolytic diseaseCurrent pathophysiologic mechanismsSetting of pregnancyPeri-partum periodPregnant patientsRBC alloantibodiesPathophysiologic mechanismsTransfusion practiceAlloantibody detectionTransfusion therapyClinical impactAlloimmunizationTransfusion communityBlood bankPregnancyDeadliest formBlood cellsAlloantibodiesFetusesDiseaseLaboratory toolPatientsTherapySettingPatient and family experience with chronic transfusion therapy for sickle cell disease: A qualitative study
Hawkins L, Sinha C, Ross D, Yee M, Quarmyne M, Krishnamurti L, Bakshi N. Patient and family experience with chronic transfusion therapy for sickle cell disease: A qualitative study. BMC Pediatrics 2020, 20: 172. PMID: 32305060, PMCID: PMC7165370, DOI: 10.1186/s12887-020-02078-w.Peer-Reviewed Original ResearchConceptsChronic transfusion therapySickle cell diseaseTransfusion therapyCell diseaseHealthcare providersPrevention of complicationsFamily experiencesStroke preventionVenous accessPatient knowledgeChildren 12Future studiesPatient participantsChelation therapySignificant patientFamily burdenSubstantial burdenPatient experiencePatientsSemi-structured interview formatTherapyComplicationsResultsFour themesBurdenInformed decision-making process
2019
Chapter 49 Neonatal and Pediatric Transfusion Medicine
Zerra P, Hendrickson J, Josephson C. Chapter 49 Neonatal and Pediatric Transfusion Medicine. 2019, 295-299. DOI: 10.1016/b978-0-12-813726-0.00049-0.Peer-Reviewed Original Research
2017
Transfusion Support of the Patient with Sickle Cell Disease Undergoing Transplantation
Hendrickson J, Fasano R. Transfusion Support of the Patient with Sickle Cell Disease Undergoing Transplantation. 2017, 111-136. DOI: 10.1007/978-3-319-62328-3_5.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationSickle cell diseaseRed blood cellsTransfusion supportTransplant physiciansConditioning regimen intensityOptimal transplant outcomesPeri-transplant periodHigher red blood cellStem cell transplantationTransfusion medicine physiciansRegimen intensityUndergoing transplantationPosttransplant periodTransplant outcomesHSCT populationCurative therapyPlatelet transfusionsSCD patientsTransfusion managementCell transplantationTransfusion therapyDonor selectionIron overloadCell disease
2016
Transfusion support for the oncology patient
Schulz W, Snyder E. Transfusion support for the oncology patient. 2016, 574-580. DOI: 10.1002/9781119013020.ch50.ChaptersOncology patientsTransfusion supportTransfusion-transmitted diseasesSafety of transfusionTA-GVHDTransplant patientsAdverse eventsDonor testingAppropriate therapyABO incompatibilityPatient populationTransfusion therapyOncologic disordersMajor therapyPatientsTransfusion servicesCellular antigensBlood componentsTherapyFrequent exposureTransfusionSpecific assessmentRiskAlloimmunizationImmunomodulation
2013
Chapter 62 Platelet Transfusion Medicine
Perrotta P, Parsons J, Rinder H, Snyder E. Chapter 62 Platelet Transfusion Medicine. 2013, 1275-1303. DOI: 10.1016/b978-0-12-387837-3.00062-6.Peer-Reviewed Original ResearchPlatelet transfusionsThrombocytopenic patientsTransfusion-related acute lung injuryTransfusion-transmitted viral infectionsAdverse effectsAcute lung injuryCommon adverse effectsPlatelet transfusion therapyLung injuryTransfusion therapyThrombocytopenic bleedingBlood therapyTransfusion reactionsBlood productsAllergic reactionsClinical experienceViral infectionTransfusionTransfusion medicineWhole bloodSeptic reactionsBleedingCell separatorPatientsTherapyChapter 47 Neonatal and Pediatric Transfusion Medicine
Hendrickson J, Josephson C. Chapter 47 Neonatal and Pediatric Transfusion Medicine. 2013, 301-305. DOI: 10.1016/b978-0-12-397164-7.00047-1.Peer-Reviewed Original Research
2012
Effects of genetic, epigenetic, and environmental factors on alloimmunization to transfused antigens: Current paradigms and future considerations
Zimring J, Stowell S, Johnsen J, Hendrickson J. Effects of genetic, epigenetic, and environmental factors on alloimmunization to transfused antigens: Current paradigms and future considerations. Transfusion Clinique Et Biologique 2012, 19: 125-131. PMID: 22682308, DOI: 10.1016/j.tracli.2012.03.002.Peer-Reviewed Original ResearchConceptsImmune systemLarge observational studiesMinority of recipientsHuman immune systemTransfused cellsContext of transfusionRed blood cellsTransfusion therapyObservational studyImmune responseAdditional antibodiesCoagulation factorsAlloimmunizationClinical barriersBlood cellsRecent mechanistic studiesRecipientsTransfusionPatientsPotential causesAntigenAntibodiesMicrobial pathogensCellsResponse
2011
Coagulation, Bleeding, and Blood Transfusion
Miller B, Hendrickson J. Coagulation, Bleeding, and Blood Transfusion. 2011, 224-254. DOI: 10.1002/9781444345186.ch11.Peer-Reviewed Original ResearchBlood transfusionBlood conservation techniquesAbnormalities of coagulationAvailable blood productsSickle cell diseaseAvailable laboratory testsVon Willebrand diseaseBlood group classificationsTransfusion compatibilityTransfusion therapyBlood productsCell diseasePharmacological interventionsCoagulation systemWillebrand diseaseMaturational differencesTransfusionCoagulation cascadeCell-based modelDiseaseCoagulationLaboratory testsBleedingThrombophiliaInfants
2009
Chapter 42 Neonatal and Pediatric Transfusion Medicine
Hendrickson J, Josephson C. Chapter 42 Neonatal and Pediatric Transfusion Medicine. 2009, 235-239. DOI: 10.1016/b978-0-12-374432-6.00042-7.Peer-Reviewed Original ResearchCardiopulmonary diseaseSevere cardiopulmonary diseaseSmall-volume transfusionsFebrile transfusion reactionsPediatric transfusion medicineHLA alloimmunizationSymptomatic anemiaMajor surgeryPediatric patientsPremature infantsCMV transmissionTransfusion therapyNeonatal patientsPhysiologic changesTransfusion reactionsImmune systemNeonatesFetal periodAnticoagulant-preservative solutionInfantsTransfusionRBC productsTransfusion medicineDlPatients
2005
Pulmonary Hypertension in Children with Sickle Cell Disease: Clinical Characteristics and Co-Morbidities.
Ambrusko S, Gunawardena S, Sakara A, Windsor B, Lanford L, Michelson P, Krishnamurti L. Pulmonary Hypertension in Children with Sickle Cell Disease: Clinical Characteristics and Co-Morbidities. Blood 2005, 106: 3791. DOI: 10.1182/blood.v106.11.3791.3791.Peer-Reviewed Original ResearchSickle cell diseasePulmonary hypertensionCell diseaseSilent strokeHepatitis CClinical characteristicsAplastic crisisCerebrovascular diseaseTransfusion therapyNocturnal enuresisTR jetTricuspid regurgitant jet velocityChronic transfusion programMoya-Moya syndromeTR jet velocityAcute chest syndromeElevated total bilirubinRestrictive lung diseaseMajority of patientsObstructive sleep apneaRegurgitant jet velocityCell-directed therapiesMiddle cerebral arteryRetrospective case reviewSickle cell patients
1978
Granulocyte transfusion therapy of experimental Pseudomonas septicemia: study of cell dose and collection technique.
Appelbaum F, Bowles C, Makuch R, Deisseroth A. Granulocyte transfusion therapy of experimental Pseudomonas septicemia: study of cell dose and collection technique. Blood 1978, 52: 323-31. PMID: 667359, DOI: 10.1182/blood.v52.2.323.bloodjournal522323.Peer-Reviewed Original ResearchGranulocyte transfusion therapy of experimental Pseudomonas septicemia: study of cell dose and collection technique
Appelbaum F, Bowles C, Makuch R, Deisseroth A. Granulocyte transfusion therapy of experimental Pseudomonas septicemia: study of cell dose and collection technique. Blood 1978, 52: 323-331. DOI: 10.1182/blood.v52.2.323.323.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply